{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:26:01Z","timestamp":1790753161159,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40262-020-00907-w","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T04:17:12Z","timestamp":1591330632000},"page":"1627-1639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine"],"prefix":"10.1007","volume":"59","author":[{"given":"Sabrina T.","family":"Wiebe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Giessmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schmidt-Gerets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Hauel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Jambrecina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin F.","family":"Fromm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0144-0895","authenticated-orcid":false,"given":"Peter","family":"Stopfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"issue":"6","key":"907_CR1","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/cpt.1360","volume":"105","author":"A Gessner","year":"2019","unstructured":"Gessner A, K\u00f6nig J, Fromm MF. Clinical aspects of transporter-mediated drug\u2013drug interactions. Clin Pharmacol Ther. 2019;105(6):1386\u201394. https:\/\/doi.org\/10.1002\/cpt.1360.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"907_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/clpt.2013.86","volume":"94","author":"KM Giacomini","year":"2013","unstructured":"Giacomini KM, Huang SM. Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther. 2013;94(1):3\u20139. https:\/\/doi.org\/10.1038\/clpt.2013.86.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"907_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215\u201336. https:\/\/doi.org\/10.1038\/nrd3028.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"907_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1124\/pr.116.013326","volume":"70","author":"F M\u00fcller","year":"2018","unstructured":"M\u00fcller F, Sharma A, K\u00f6nig J, Fromm MF. Biomarkers for in vivo assessment of transporter function. Pharmacol Rev. 2018;70(2):246\u201377. https:\/\/doi.org\/10.1124\/pr.116.013326.","journal-title":"Pharmacol Rev"},{"key":"907_CR5","unstructured":"EMA-CHMP. Guideline on the investigation of drug interactions: final (CPMP\/EWP\/560\/95\/Rev. 1 corr. 2). 2012. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf. Accessed 14 Jun 2019."},{"key":"907_CR6","unstructured":"US FDA. In vitro drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. 2020. https:\/\/www.fda.gov\/media\/134582\/download. Accessed 18 Jan 2020."},{"key":"907_CR7","unstructured":"US FDA. Guidance for industry: clinical drug interaction studies: study design, data analysis, and clinical implications (draft guidance). 2017. https:\/\/www.fda.gov\/media\/82734\/download. Accessed 14 Jun 2019."},{"issue":"5","key":"907_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0009-9236(03)00229-7","volume":"74","author":"S Chainuvati","year":"2003","unstructured":"Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the \"Cooperstown 5+1 cocktail\". Clin Pharmacol Ther. 2003;74(5):437\u201347. https:\/\/doi.org\/10.1016\/s0009-9236(03)00229-7.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"907_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1365-2125.2009.03548.x","volume":"68","author":"S Turpault","year":"2009","unstructured":"Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009;68(6):928\u201335. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03548.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"907_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cpt.406","volume":"100","author":"P Stopfer","year":"2016","unstructured":"Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, et al. Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin. Clin Pharmacol Ther. 2016;100(3):259\u201367. https:\/\/doi.org\/10.1002\/cpt.406.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"907_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/cpt.588","volume":"101","author":"L Zhang","year":"2017","unstructured":"Zhang L, Sparreboom A. Predicting transporter-mediated drug interactions: commentary on: \"Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatin\" and \"Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A\". Clin Pharmacol Ther. 2017;101(4):447\u20139. https:\/\/doi.org\/10.1002\/cpt.588.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"907_CR12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/cpt.1216","volume":"104","author":"X Chu","year":"2018","unstructured":"Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, et al. Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the International Transporter Consortium. Clin Pharmacol Ther. 2018;104(5):836\u201364. https:\/\/doi.org\/10.1002\/cpt.1216.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"907_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/cpt.525","volume":"101","author":"T Prueksaritanont","year":"2017","unstructured":"Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, et al. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017;101(4):519\u201330. https:\/\/doi.org\/10.1002\/cpt.525.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"907_CR14","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/cpt.1564","volume":"106","author":"C Trueck","year":"2019","unstructured":"Trueck C, Hsin C-H, Scherf-Clavel O, Schaeffeler E, Lenssen R, Gazzaz M, et al. A clinical DDI study assessing a novel drug transporter phenotyping cocktail with adefovir, sitagliptin, metformin, pitavastatin and digoxin. Clin Pharmacol Ther. 2019;106(6):1398\u2013407. https:\/\/doi.org\/10.1002\/cpt.1564.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"907_CR15","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1002\/jps.24489","volume":"104","author":"T Ebner","year":"2015","unstructured":"Ebner T, Ishiguro N, Taub ME. The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail. J Pharm Sci. 2015;104(9):3220\u20138. https:\/\/doi.org\/10.1002\/jps.24489.","journal-title":"J Pharm Sci"},{"issue":"1","key":"907_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13318-017-0427-9","volume":"43","author":"P Stopfer","year":"2018","unstructured":"Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, et al. Effects of metformin and furosemide on rosuvastatin pharmacokinetics in healthy volunteers: implications for their use as probe drugs in a transporter cocktail. Eur J Drug Metab Pharmacokinet. 2018;43(1):69\u201380. https:\/\/doi.org\/10.1007\/s13318-017-0427-9.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"907_CR17","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/bcp.13609","volume":"84","author":"P Stopfer","year":"2018","unstructured":"Stopfer P, Giessmann T, Hohl K, Hutzel S, Schmidt S, Gansser D, et al. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug\u2013drug interactions. Br J Clin Pharmacol. 2018;84(9):1941\u20139. https:\/\/doi.org\/10.1111\/bcp.13609.","journal-title":"Br J Clin Pharmacol"},{"issue":"1\u20132","key":"907_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cca.2009.04.003","volume":"405","author":"YJ He","year":"2009","unstructured":"He YJ, Zhang W, Chen Y, Guo D, Tu JH, Xu LY, et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T%3eC polymorphism. Clin Chim Acta. 2009;405(1\u20132):49\u201352. https:\/\/doi.org\/10.1016\/j.cca.2009.04.003.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"907_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jps.2600690526","volume":"69","author":"DE Smith","year":"1980","unstructured":"Smith DE, Gee WL, Brater DC, Lin ET, Benet LZ. Preliminary evaluation of furosemide-probenecid interaction in humans. J Pharm Sci. 1980;69(5):571\u20135.","journal-title":"J Pharm Sci"},{"issue":"2","key":"907_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF00542456","volume":"22","author":"KE Pedersen","year":"1982","unstructured":"Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Pedersen KK. The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol. 1982;22(2):123\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"907_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/bf01037945","volume":"25","author":"A Somogyi","year":"1983","unstructured":"Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol. 1983;25(3):339\u201345. https:\/\/doi.org\/10.1007\/bf01037945.","journal-title":"Eur J Clin Pharmacol"},{"key":"907_CR22","unstructured":"US FDA. Guidance for industry: bioanalytical method validation. 2001. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm070107.pdf. Accessed 13 Mar 2017."},{"key":"907_CR23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/00031305.1989.10475628","volume":"43","author":"LL Kupper","year":"1989","unstructured":"Kupper LL, Hafner KB. How appropriate are popular sample size formulas? Am Stat. 1989;43:101\u20135.","journal-title":"Am Stat"},{"issue":"3","key":"907_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bcp.12377","volume":"78","author":"T Prueksaritanont","year":"2014","unstructured":"Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol. 2014;78(3):587\u201398. https:\/\/doi.org\/10.1111\/bcp.12377.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"907_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.116.234914","volume":"358","author":"Y Lai","year":"2016","unstructured":"Lai Y, Mandlekar S, Shen H, Holenarsipur VK, Langish R, Rajanna P, et al. Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug\u2013drug interactions mediated by organic anion transporting polypeptide inhibition. J Pharmacol Exp Ther. 2016;358(3):397\u2013404. https:\/\/doi.org\/10.1124\/jpet.116.234914.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"907_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/clpt.2010.271","volume":"89","author":"ML Reitman","year":"2011","unstructured":"Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug\u2013drug interaction trial design. Clin Pharmacol Ther. 2011;89(2):234\u201342. https:\/\/doi.org\/10.1038\/clpt.2010.271.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"907_CR27","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1124\/jpet.103.061770","volume":"308","author":"YY Lau","year":"2004","unstructured":"Lau YY, Wu CY, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther. 2004;308(3):1040\u20135. https:\/\/doi.org\/10.1124\/jpet.103.061770.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"907_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1124\/dmd.118.080408","volume":"46","author":"K Kaneko","year":"2018","unstructured":"Kaneko K, Tanaka M, Ishii A, Katayama Y, Nakaoka T, Irie S, et al. A clinical quantitative evaluation of hepatobiliary transport of [(11)C]dehydropravastatin in humans using positron emission tomography. Drug Metab Dispos. 2018;46(5):719\u201328. https:\/\/doi.org\/10.1124\/dmd.118.080408.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"907_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/clpt.2010.266","volume":"89","author":"SK Cho","year":"2011","unstructured":"Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, et al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011;89(3):416\u201321. https:\/\/doi.org\/10.1038\/clpt.2010.266.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"907_CR30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/clpt.1983.55","volume":"33","author":"GG Belz","year":"1983","unstructured":"Belz GG, Doering W, Munkes R, Matthews J. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther. 1983;33(4):410\u20137. https:\/\/doi.org\/10.1038\/clpt.1983.55.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"907_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/clpt.1988.93","volume":"43","author":"SM Rodin","year":"1988","unstructured":"Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther. 1988;43(6):668\u201372. https:\/\/doi.org\/10.1038\/clpt.1988.93.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"907_CR32","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1161\/01.cir.65.5.998","volume":"65","author":"HO Klein","year":"1982","unstructured":"Klein HO, Lang R, Weiss E, Di Segni E, Libhaber C, Guerrero J, et al. The influence of verapamil on serum digoxin concentration. Circulation. 1982;65(5):998\u20131003. https:\/\/doi.org\/10.1161\/01.cir.65.5.998.","journal-title":"Circulation"},{"issue":"6","key":"907_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1161\/01.cir.65.6.1163","volume":"65","author":"JB Schwartz","year":"1982","unstructured":"Schwartz JB, Keefe D, Kates RE, Kirsten E, Harrison DC. Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation. 1982;65(6):1163\u201370. https:\/\/doi.org\/10.1161\/01.cir.65.6.1163.","journal-title":"Circulation"},{"issue":"2","key":"907_CR34","first-page":"376","volume":"293","author":"C Pauli-Magnus","year":"2000","unstructured":"Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000;293(2):376\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"907_CR35","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/bcp.12476","volume":"78","author":"SK Cho","year":"2014","unstructured":"Cho SK, Kim CO, Park ES, Chung JY. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. Br J Clin Pharmacol. 2014;78(6):1426\u201332. https:\/\/doi.org\/10.1111\/bcp.12476.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"907_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2125.1987.tb03090.x","volume":"23","author":"A Somogyi","year":"1987","unstructured":"Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23(5):545\u201351. https:\/\/doi.org\/10.1111\/j.1365-2125.1987.tb03090.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"907_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/FPC.0b013e328302cd41","volume":"18","author":"ZJ Wang","year":"2008","unstructured":"Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genom. 2008;18(7):637\u201345. https:\/\/doi.org\/10.1097\/FPC.0b013e328302cd41.","journal-title":"Pharmacogenet Genom"},{"issue":"6","key":"907_CR38","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/clpt.2011.36","volume":"89","author":"H Kusuhara","year":"2011","unstructured":"Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther. 2011;89(6):837\u201344. https:\/\/doi.org\/10.1038\/clpt.2011.36.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"907_CR39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/096032718500400405","volume":"4","author":"P Crome","year":"1985","unstructured":"Crome P, Curl B, Holt D, Volans GN, Bennett PN, Cole DS. Digoxin and cimetidine: investigation of the potential for a drug interaction. Hum Toxicol. 1985;4(4):391\u20139.","journal-title":"Hum Toxicol"},{"issue":"7","key":"907_CR40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/00498250500136676","volume":"35","author":"M Yamazaki","year":"2005","unstructured":"Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica. 2005;35(7):737\u201353. https:\/\/doi.org\/10.1080\/00498250500136676.","journal-title":"Xenobiotica"},{"issue":"2","key":"907_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1254\/jphs.94.197","volume":"94","author":"S Khamdang","year":"2004","unstructured":"Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, et al. Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004;94(2):197\u2013202. https:\/\/doi.org\/10.1254\/jphs.94.197.","journal-title":"J Pharmacol Sci"},{"issue":"6","key":"907_CR42","first-page":"692","volume":"39","author":"TB Vree","year":"1995","unstructured":"Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol. 1995;39(6):692\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"907_CR43","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1124\/dmd.118.081794","volume":"46","author":"RE Kosa","year":"2018","unstructured":"Kosa RE, Lazzaro S, Bi YA, Tierney B, Gates D, Modi S, et al. Simultaneous assessment of transporter-mediated drug\u2013drug interactions using a probe drug cocktail in cynomolgus monkey. Drug Metab Dispos. 2018;46(8):1179\u201389. https:\/\/doi.org\/10.1124\/dmd.118.081794.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"907_CR44","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1124\/jpet.107.125831","volume":"322","author":"AS Windass","year":"2007","unstructured":"Windass AS, Lowes S, Wang Y, Brown CD. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007;322(3):1221\u20137. https:\/\/doi.org\/10.1124\/jpet.107.125831.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"907_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2133\/dmpk.17.23","volume":"17","author":"M Horikawa","year":"2002","unstructured":"Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet. 2002;17(1):23\u201333.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"907_CR46","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1124\/dmd.107.017814","volume":"36","author":"S Matsushima","year":"2008","unstructured":"Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2008;36(4):663\u20139. https:\/\/doi.org\/10.1124\/dmd.107.017814.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"907_CR47","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1124\/dmd.106.009290","volume":"34","author":"M Hirano","year":"2006","unstructured":"Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34(7):1229\u2013366. https:\/\/doi.org\/10.1124\/dmd.106.009290.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"907_CR48","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/clpt.2013.27","volume":"93","author":"B Halama","year":"2013","unstructured":"Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther. 2013;93(6):564\u201371. https:\/\/doi.org\/10.1038\/clpt.2013.27.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00907-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00907-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00907-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T23:50:49Z","timestamp":1722988249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00907-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00907-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"5 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was funded by Boehringer Ingelheim Pharma GmbH & Co. KG, the sponsor of the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kathrin Hohl and Edith Hauel were contracted by Boehringer Ingelheim as external statistician and external medical writer, respectively. Alen Jambrecina was the Principal Investigator contracted by Boehringer Ingelheim. Gerd Mikus and Martin F. Fromm have paid consultancy agreements with Boehringer Ingelheim. All other authors are employees of Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical trial protocol was approved by the Independent Ethics Committee of the Chamber of Physicians of Hamburg, Germany, and the Federal Institute for Drugs and Medicinal Products (BfArM). The trial was carried out in compliance with the principles of the Declaration of Helsinki and in accordance with the International Council for Harmonization Guidelines for Good Clinical Practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All subjects in the study provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}